Psychiatric Center Copenhagen, Department O, Copenhagen, Denmark; Research Center for Prevention and Health, Rigshospitalet-Glostrup, Glostrup, Denmark.
Psychiatric Center Frederiksberg, Frederiksberg, Denmark; Research Center for Prevention and Health, Rigshospitalet-Glostrup, Glostrup, Denmark.
Int J Cardiol. 2017 Nov 1;246:1-6. doi: 10.1016/j.ijcard.2017.05.105.
We examined if treatment with acetylsalicylic acid (ASA), non-steroid anti-inflammatory drugs (NSAID), or statins after acute coronary syndrome (ACS) are associated with decreased risk of depression.
This register-based cohort study included all individuals with a first-time hospital admissions with an ACS diagnosis registered between January 2001 to December 2009 (N=91,842) and a comparable reference population without ACS (N=91,860). Information of ASA, NSAID, and statin use were retrieved from a national prescription register. The study population was followed for hospitalization with depression or receiving prescription of antidepressant medication for up to one year after ACS or study entry (early depression) or one to twelve years after ACS or study entry (late depression).
ASA use after ACS was associated with decreased risk of early depression with hazard ratios (HR) of 0.89 (95% confidence interval 0.85-0.93) but not with late depression 0.96 (0.90-1.01). The corresponding HRs for statin were 0.90 (0.86-0.94) and 0.86 (0.82-0.90). In the non-ACS population, statin use was not associated with neither early nor late depression (HRs 1.04 (0.96-1.12) and 1.00 (0.95-1.06)), while ASA was associated with increased risk of late (HR 1.09 (1.04-1.14)) but not early depression (HR 1.03 (0.97-1.09)). In both populations, NSAID use was associated with increased risk of late but not early depression.
Use of ASA or statins were associated with decreased risk of depression in ACS patients but not in individuals without ACS, while use of NSAID was associated with increased risk of late depression in both populations.
我们研究了急性冠脉综合征(ACS)后使用乙酰水杨酸(ASA)、非甾体抗炎药(NSAID)或他汀类药物治疗是否与降低抑郁风险相关。
本基于登记的队列研究纳入了 2001 年 1 月至 2009 年 12 月期间首次因 ACS 住院的所有患者(n=91842)和无 ACS 的可比参考人群(n=91860)。ASA、NSAID 和他汀类药物的使用信息从国家处方登记处获得。研究人群在 ACS 后或研究入组后一年内(早期抑郁)或 ACS 后或研究入组后一至十二年(晚期抑郁)因住院治疗抑郁症或接受抗抑郁药物处方而被随访。
ACS 后使用 ASA 与早期抑郁风险降低相关,风险比(HR)为 0.89(95%置信区间 0.85-0.93),但与晚期抑郁无关(HR 0.96(0.90-1.01))。他汀类药物的相应 HR 为 0.90(0.86-0.94)和 0.86(0.82-0.90)。在非 ACS 人群中,他汀类药物的使用与早期或晚期抑郁均无关(HR 1.04(0.96-1.12)和 1.00(0.95-1.06)),而 ASA 与晚期抑郁风险增加相关(HR 1.09(1.04-1.14))但与早期抑郁无关(HR 1.03(0.97-1.09))。在两个人群中,NSAID 的使用均与晚期但非早期抑郁风险增加相关。
ACS 患者使用 ASA 或他汀类药物与抑郁风险降低相关,但在无 ACS 的个体中则不然,而 NSAID 的使用与两个人群中晚期抑郁风险增加相关。